Treating Immunodeficiency through HSC Gene Therapy

Hacein-Bey-Abina, 2008, Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1, J. Clin. Invest., 118, 3132, 10.1172/JCI35700 Howe, 2008, Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients, J. Clin. Invest., 118, 3143, 10.1172/JCI35798 Braun, 2014, Gene therapy for Wiskott–Aldrich syndrome – long-term efficacy and genotoxicity, Sci. Transl. Med., 6, 227ra233, 10.1126/scitranslmed.3007280 Boztug, 2010, Stem-cell gene therapy for the Wiskott–Aldrich syndrome, N. Engl. J. Med., 363, 1918, 10.1056/NEJMoa1003548 Ott, 2006, Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1, Nat. Med., 12, 401, 10.1038/nm1393 Stein, 2010, Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease, Nat. Med., 16, 198, 10.1038/nm.2088 Hacein-Bey-Abina, 2014, A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency, N. Engl. J. Med., 371, 1407, 10.1056/NEJMoa1404588 Aiuti, 2013, Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott–Aldrich syndrome, Science, 341, 1233151, 10.1126/science.1233151 Hacein-Bey Abina, 2015, Outcomes following gene therapy in patients with severe Wiskott–Aldrich syndrome, JAMA, 313, 1550, 10.1001/jama.2015.3253 Gaspar, 2015, Immunological and metabolic correction after lentiviral gene therapy for ADA deficiency, Mol. Ther., 23, S102, 10.1016/S1525-0016(16)33866-7 Gaspar, 2009, How I treat ADA deficiency, Blood, 114, 3524, 10.1182/blood-2009-06-189209 Blaese, 1995, T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years, Science, 270, 475, 10.1126/science.270.5235.475 Bordignon, 1995, Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients, Science, 270, 470, 10.1126/science.270.5235.470 Aiuti, 2002, Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning, Science, 296, 2410, 10.1126/science.1070104 Gaspar, 2006, Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning, Mol. Ther., 14, 505, 10.1016/j.ymthe.2006.06.007 Aiuti, 2009, Gene therapy for immunodeficiency due to adenosine deaminase deficiency, N. Engl. J. Med., 360, 447, 10.1056/NEJMoa0805817 Gaspar, 2011, Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction, Sci. Transl. Med., 3, 97ra80, 10.1126/scitranslmed.3002716 Candotti, 2012, Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans, Blood, 120, 3635, 10.1182/blood-2012-02-400937 Carbonaro, 2012, Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction, Blood, 120, 3677, 10.1182/blood-2012-02-408591 Otsu, 2015, Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning, J. Clin. Immunol., 35, 384, 10.1007/s10875-015-0157-1 Gaspar, 2011, Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency, Sci. Transl. Med., 3, 97ra79, 10.1126/scitranslmed.3002715 Gaspar, 2004, Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector, Lancet, 364, 2181, 10.1016/S0140-6736(04)17590-9 Hacein-Bey-Abina, 2010, Efficacy of gene therapy for X-linked severe combined immunodeficiency, N. Engl. J. Med., 363, 355, 10.1056/NEJMoa1000164 Touzot, 2015, Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1, Blood, 125, 3563, 10.1182/blood-2014-12-616003 de ravin, 2015, Lentiviral hematopoietic stem cell gene therapy for older patients with X-linked severe combined immune deficiency, Blood, 126, 261, 10.1182/blood.V126.23.261.261 Sullivan, 1994, A multiinstitutional survey of the Wiskott–Aldrich syndrome, J. Pediatr., 125, 876, 10.1016/S0022-3476(05)82002-5 Goebel, 2003, Gene therapy for chronic granulomatous disease, Acta Haematol., 110, 86, 10.1159/000072457 Bianchi, 2009, Restoration of NET formation by gene therapy in CGD controls aspergillosis, Blood, 114, 2619, 10.1182/blood-2009-05-221606 Kang, 2010, Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils, Blood, 115, 783, 10.1182/blood-2009-05-222760 Kang, 2011, Retroviral gene therapy for X-linked chronic granulomatous disease: results from Phase I/II trial, Mol. Ther., 19, 2092, 10.1038/mt.2011.166 Siler, 2015, Successful combination of sequential gene therapy and rescue allo-HSCT in two children with X-CGD – importance of timing, Curr. Gene Ther., 15, 416, 10.2174/1566523215666150515145255 Stein, 2013, From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease, Hum. Gene Ther. Clin. Dev., 24, 86, 10.1089/humc.2013.019 Chiriaco, 2014, Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis, Mol. Ther., 22, 1472, 10.1038/mt.2014.87 Santilli, 2011, Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells, Mol. Ther., 19, 122, 10.1038/mt.2010.226 Slatter, 2010, Primary immunodeficiencies associated with DNA-repair disorders, Expert Rev. Mol. Med., 12, e9, 10.1017/S1462399410001419 Benjelloun, 2008, Stable and functional lymphoid reconstitution in Artemis-deficient mice following lentiviral Artemis gene transfer into hematopoietic stem cells, Mol. Ther., 16, 1490, 10.1038/mt.2008.118 Mostoslavsky, 2006, Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer, Proc. Natl. Acad. Sci. U.S.A., 103, 16406, 10.1073/pnas.0608130103 Pike-Overzet, 2011, Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer, Leukemia, 25, 1471, 10.1038/leu.2011.106 van Til, 2014, Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome, J. Allergy Clin. Immunol., 133, 1116, 10.1016/j.jaci.2013.10.009 van Til, 2012, Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene, Mol. Ther., 20, 1968, 10.1038/mt.2012.110 Yates, 2002, Gene therapy of RAG-2−/− mice: sustained correction of the immunodeficiency, Blood, 100, 3942, 10.1182/blood-2002-03-0782 Bauer, 2000, Gene therapy for leukocyte adhesion deficiency, Curr. Opin. Mol. Ther., 2, 383 Nelson, 2010, Lentiviral vectors incorporating a human elongation factor 1α promoter for the treatment of canine leukocyte adhesion deficiency, Gene Ther., 17, 672, 10.1038/gt.2010.7 Hunter, 2011, Gene therapy of canine leukocyte adhesion deficiency using lentiviral vectors with human CD11b and CD18 promoters driving canine CD18 expression, Mol. Ther., 19, 113, 10.1038/mt.2010.203 Hunter, 2011, Gene therapy for canine leukocyte adhesion deficiency with lentiviral vectors using the murine stem cell virus and human phosphoglycerate kinase promoters, Hum. Gene Ther., 22, 689, 10.1089/hum.2010.130 Bauer, 2008, Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors, Nat. Med., 14, 93, 10.1038/nm1695 Ng, 2010, Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK, Leukemia, 24, 1617, 10.1038/leu.2010.140 Sather, 2011, Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders, Mol. Ther., 19, 515, 10.1038/mt.2010.259 Kerns, 2010, B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia, Blood, 115, 2146, 10.1182/blood-2009-09-241869 Brown, 1998, Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice, Nat. Med., 4, 1253, 10.1038/3233 Romero, 2011, A tissue-specific, activation-inducible, lentiviral vector regulated by human CD40L proximal promoter sequences, Gene Ther., 18, 364, 10.1038/gt.2010.144 Fernandez-Rubio, 2015, Regulated expression of murine CD40L by a lentiviral vector transcriptionally targeted through its endogenous promoter, J. Gene Med., 17, 219, 10.1002/jgm.2837 Carmo, 2015, Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency, Mol. Ther., 23, 737, 10.1038/mt.2014.242 Rivat, 2013, SAP gene transfer restores cellular and humoral immune function in a murine model of X-linked lymphoproliferative disease, Blood, 121, 1073, 10.1182/blood-2012-07-445858 Passerini, 2013, CD4+ T cells from IPEX patients convert into functional and stable regulatory T cells by FOXP3 gene transfer, Sci. Transl. Med., 5, 215ra174, 10.1126/scitranslmed.3007320 Ott de Bruin, 2015, Novel genome-editing tools to model and correct primary immunodeficiencies, Front. Immunol., 6, 250, 10.3389/fimmu.2015.00250 Tebas, 2014, Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV, N. Engl. J. Med., 370, 901, 10.1056/NEJMoa1300662 Genovese, 2014, Targeted genome editing in human repopulating haematopoietic stem cells, Nature, 510, 235, 10.1038/nature13420 Merling, 2015, An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous disease, Mol. Ther., 23, 147, 10.1038/mt.2014.195 Dreyer, 2015, TALEN-mediated functional correction of X-linked chronic granulomatous disease in patient-derived induced pluripotent stem cells, Biomaterials, 69, 191, 10.1016/j.biomaterials.2015.07.057 Flynn, 2015, CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells, Exp. Hematol., 43, 838, 10.1016/j.exphem.2015.06.002 Reardon, 2015, Leukaemia success heralds wave of gene-editing therapies, Nature, 527, 146, 10.1038/nature.2015.18737